Vicore Pharma Holding AB (publ) (STO:VICO)

Vicore Pharma Holding AB Income Statement

Financials in millions SEK. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	109.35	-	-	-	-
Gross Profit	109.35	-	-	-	-
Selling, General & Admin	50.44	44.6	37.53	21.61	24.99
Research & Development	249.26	276.29	249.97	271.81	142.02
Operating Expenses	299.71	320.89	287.49	293.42	167.01
Operating Income	-190.36	-320.89	-287.49	-293.42	-167.01
Interest Expense	-0.01	-0	-0.01	-0.01	-0.01
Interest & Investment Income	25.31	10.54	0.91	0.65	0.82
Currency Exchange Gain (Loss)	-3.83	-0.62	-1.75	-1.83	-0.07
EBT Excluding Unusual Items	-168.89	-310.97	-288.34	-294.61	-166.27
Gain (Loss) on Sale of Investments	-	-0.36	-0.47	-2.12	1.41
Other Unusual Items	-	-	-	-	17.54
Pretax Income	-168.89	-311.33	-288.81	-296.74	-147.32
Income Tax Expense	-0.26	-0.38	-0.38	-0.25	-0.45
Net Income	-168.63	-310.94	-288.42	-296.48	-146.86
Net Income to Common	-168.63	-310.94	-288.42	-296.48	-146.86
Shares Outstanding (Basic)	138	97	72	70	54
Shares Outstanding (Diluted)	138	97	72	70	54
Shares Change (YoY)	42.65%	33.71%	3.64%	28.44%	26.04%
EPS (Basic)	-1.22	-3.22	-3.99	-4.25	-2.71
EPS (Diluted)	-1.22	-3.22	-3.99	-4.25	-2.71
Free Cash Flow	-164.95	-249.58	-299.92	-265.17	-119.94
Free Cash Flow Per Share	-1.20	-2.58	-4.15	-3.81	-2.21
Gross Margin	100.00%	-	-	-	-
Operating Margin	-174.09%	-	-	-	-
Profit Margin	-154.22%	-	-	-	-
Free Cash Flow Margin	-150.85%	-	-	-	-
EBITDA	-188.12	-317.47	-283.88	-290.06	-163.65
EBITDA Margin	-172.04%	-	-	-	-
D&A For EBITDA	2.24	3.42	3.61	3.36	3.36
EBIT	-190.36	-320.89	-287.49	-293.42	-167.01
EBIT Margin	-174.09%	-	-	-	-

Updated Feb 27, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.